更新于：2024-11-01

Metastatic gallbladder cancer

转移性胆囊癌

更新于：2024-11-01

基本信息

别名

Cancer metastatic to gallbladder、Gallbladder cancer metastatic、Metastatic Malignant Neoplasm in the Gallbladder

+ [15]

简介

A malignant neoplasm that has spread to the gallbladder from another anatomic site. Representative examples include metastatic melanoma, and metastatic carcinomas from the breast and the stomach.

关联

项与转移性胆囊癌相关的药物

Panitumumab

帕尼单抗

靶点

EGFR

作用机制

EGFR拮抗剂

在研机构

Takeda Pharmaceutical Co., Ltd. [+3]

原研机构

Amgen, Inc.

在研适应症

转移性结直肠癌 [+3]

非在研适应症

食管腺癌 [+51]

最高研发阶段批准上市

首次获批国家/地区

美国

首次获批日期2006-09-27

Bevacizumab

贝伐珠单抗

靶点

VEGF-A

作用机制

VEGF-A抑制剂 [+1]

在研机构

National Cancer Institute [+23]

原研机构

Genentech, Inc.

在研适应症

不可切除的肝细胞癌 [+189]

非在研适应症

异戊酸血症 [+268]

最高研发阶段批准上市

首次获批国家/地区

美国

首次获批日期2004-02-26

Oxaliplatin

奥沙利铂

靶点

DNA

作用机制

DNA抑制剂

在研机构

Yakult Honsha Co., Ltd. [+5]

原研机构

Sanofi

在研适应症

小肠癌 [+18]

非在研适应症

急性髓性白血病 [+87]

最高研发阶段批准上市

首次获批国家/地区

中国

首次获批日期2000-01-01

项与转移性胆囊癌相关的临床试验

NCT06591650 / Not yet recruiting临床2期IIT

A Phase II Study of Gemcitabine, Cisplatin, Nab-Paclitaxel, and Durvalumab in Locally Advanced or Metastatic Gallbladder Cancer

This phase II trail will evaluate the efficacy and safety of combining gemcitabine hydrochloride, cisplatin, nab-paclitaxel (paclitaxel albumin-stabilized nanoparticle formulation), with durvalumab in treating patients who have locally advanced or metastatic gallbladder cancer.
Drugs used in chemotherapy, such as gemcitabine hydrochloride, cisplatin, and nab-paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Durvalumab is a type of drug called a monoclonal antibody, which selectively blocks PD-L1 binding to PD-1. This anti-PD-L1 treatment works by allowing the immune system to detect your cancer and reactivates the immune response.

开始日期2024-09-10

申办/合作机构

复旦大学

NCT04941287 / Active, not recruiting临床2期IIT

A Randomized Phase 2 Study of Combination Atezolizumab and CDX-1127 (Varlilumab) With or Without Addition of Cobimetinib in Previously Treated Unresectable Biliary Tract Cancers

This phase II trial investigates the effect of combining two immune therapies, atezolizumab and CDX-1127 (varlilumab), with or without cobimetinib, in treating patients with biliary tract cancer that cannot be removed by surgery (unresectable). Immunotherapy with monoclonal antibodies, such as atezolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Varlilumab is an immune agonist antibody that may further strengthen the immune system's attack on the cancer. Cobimetinib is in a class of medications called kinase inhibitors. It works by blocking the action of an abnormal protein that signals cancer cells to multiply. This helps slow or stop the spread of cancer cells. Giving atezolizumab in combination with varlilumab and cobimetinib may work better than atezolizumab and varlilumab alone in treating patients with unresectable biliary tract cancer.

开始日期2021-12-15

申办/合作机构

National Cancer Institute

NCT01308840 / Completed临床2期IIT

Phase II Study of Gemcitabine, Oxaliplatin in Combination With Panitumumab in Kras/B-raf Wild-Type Unresectable or Metastatic Biliary Track and Gallbladder Cancer

The purpose of this study is to determine disease response of GEMOX-Panitumumab (GEMOX-P) in KRAS/ BRAF wild-type, Stage IV, biliary tract and gallbladder cancer patients who have previously not received chemotherapy. This study will also examine the potential toxicities, progression-free and overall survival in this population.

开始日期2010-12-01

申办/合作机构

University of Rochester

[+1]

100 项与转移性胆囊癌相关的临床结果

登录后查看更多信息

100 项与转移性胆囊癌相关的转化医学

登录后查看更多信息

0 项与转移性胆囊癌相关的专利（医药）

登录后查看更多信息

184

项与转移性胆囊癌相关的文献（医药）

2024-10-01·International Journal of Surgery Case Reports

Gallbladder tuberculosis mimicking carcinoma: A case report of a rare entity

Article

作者: Maity, Rick ; Mukherjee, Souradip ; Biswas, Jyotirmoy ; Dhali, Arkadeep ; Dhali, Gopal Krishna

INTRODUCTIONGallbladder TB (GBTB) is a rare disease with a non-specific presentation, simulating cholecystitis and gallbladder malignancies. We describe a rare case of infiltrative GBTB with biliary strictures in a young female who was initially diagnosed with metastatic gallbladder carcinoma.CASE PRESENTATIONA 33-year-old female presented with recurrent episodes of obstructive jaundice, significant weight loss, fatigue, and oligomenorrhoea. Imaging studies revealed features of locally advanced gallbladder carcinoma with proximal and distal common bile duct strictures. However, biopsy of the liver tissue surrounding the gallbladder mass confirmed necrotizing granulomatous inflammation with similar findings from fine needle aspiration of the cervical lymph node. Along with the histopathological findings, radiological evidence of pulmonary tuberculosis confirmed the diagnosis of infiltrative GBTB. The patient was successfully managed with anti-tubercular drugs along with biliary decompression.DISCUSSIONThe rarity of GBTB is attributed to the high alkalinity of bile and bile acids, which afford protection against tubercle bacilli. Patients commonly present with abdominal pain, fever, abdominal lump, anorexia, and weight loss. Biliary strictures, though rare, have been described in GBTB and simulate cholangiocarcinoma. Due to the non-specific findings of pre-operative laboratory and radiological investigations, most patients are taken up for surgery and diagnosed with TB on post-operative histological analysis.CONCLUSIONGallbladder TB is a rare disease which poses a diagnostic challenge because it lacks any pathognomonic features. A tissue diagnosis must be carried out before confirming gallbladder and biliary tract malignancies. Physicians in TB-endemic regions should possess a high index of suspicion for diagnosing GBTB.

2024-10-01·Journal of Clinical Ultrasound

Metastatic melanoma of the gallbladder: A case report and systematic review

Review

作者: Tang, Congyu ; Yu, Qing ; Chen, Jianfei ; Geng, Zhidan ; Luo, Rongkui ; Yuan, Haixia

AbstractWe report a case of metastatic melanoma of the gallbladder diagnosed by contrast‐enhanced ultrasound and systematically review the characteristics of transabdominal ultrasound, clinical manifestations, and treatment methods of gallbladder metastatic melanoma in order to provide reference ideas for the diagnosis and treatment of metastatic melanoma of gallbladder.

2024-08-01·Gan to kagaku ryoho. Cancer & chemotherapy

[A Case of Radical Hepatectomy in a Patient with Recurrent Liver Metastasis of Gallbladder Cancer after Successful Chemotherapy with GC+Durvalumab].

Article

作者: Fukushima, Kenji ; Gon, Hidetoshi ; Arai, Keisuke ; So, Shinichi ; Yanagimoto, Hiroaki ; Asari, Sadaki ; Fukumoto, Takumi ; Toyama, Hirochika ; Miyake, Taiichiro ; Komatsu, Shohei ; Kido, Masahiro ; Urade, Takeshi

A 49-year-old man underwent an open cholecystectomy for advanced gallbladder cancer in 2021. Three months after surgery, the patient underwent an additional resection, which showed no malignant findings, but 12 months after surgery, contrast-enhanced CT and MRI showed a new mass lesion in segment 8 of the liver, and the patient was diagnosed with postoperative hepatic metastatic recurrence of gallbladder cancer. After referral to our institution, he received 1 course of gemcitabine+cisplatin(GC)therapy and 8 courses of gemcitabine+cisplatin+durvalumab(GCD)therapy. Contrast- enhanced CT and MRI showed that the metastases had shrunk, and PET scan showed no FDG accumulation. Two months after completion of chemotherapy, there was no evidence of metastatic enlargement and new metastasis including distant metastasis, and the patient was referred to our department. Since curative resection was expected, a laparoscopic partial hepatectomy of segment 8 of the liver was performed. Pathological diagnosis revealed no residual tumor. If the metastases could be well controlled by systemic chemotherapy, hepatectomy for hepatic metastases of biliary tract cancer could be a treatment option.

项与转移性胆囊癌相关的新闻（医药）

2024-06-12

·drugs

Generation X Experiencing Larger Per-Capita Increases in Cancer Incidence

WEDNESDAY, June 12, 2024 -- Generation X is experiencing larger per-capita increases in the incidence of cancers than Baby Boomers, according to a study published online June 10 in JAMA Network Open . Philip S. Rosenberg, Ph.D., and Adalberto Miranda-Filho, Ph.D., from the National Cancer Institute in Bethesda, Maryland, estimated invasive cancer incidence trends in successive generations. Stratum-specific semiparametric age-period-cohort models were fitted and incidence was calculated per 100,000 person-years at the reference age of 60 years for single-year birth cohorts from 1908 through 1983 (fitted cohort patterns [FCPs]). The FCPs and FCP incidence rate ratios [IRRs] were compared for Generation X (born 1965 to 1980) and Baby Boomers (born 1946 to 1964). The analysis included 3.8 million individuals with invasive cancer. The researchers found that the FCP IRRs among women were significantly increased for thyroid, kidney, rectal, corpus uterine, colon, and pancreatic cancers, non-Hodgkin lymphoma, and leukemia in Generation X versus Baby Boomers (FCP IRRs, 2.76, 1.99, 1.84, 1.75, 1.56, 1.39, 1,40, and 1.27, respectively). Among men, increases were seen for thyroid, kidney, rectal, colon, and prostate cancers and leukemia (2.16, 2.14, 1.80, 1.60, 1,25, and 1.34, respectively). Among women, decreases were seen in lung and cervical cancer incidence (IRRs, 0.60 and 0.71, respectively), while among men, decreases were seen in lung, liver, and gallbladder cancer and non-Hodgkin lymphoma (IRRs, 0.51, 0.76, 0.85, and 0.75, respectively). Increases in the incidence of cancers numerically overtook decreasing incidence in all groups except Asian or Pacific Islander men, resulting in higher FCPs in Generation X than Baby Boomers for all cancers combined. "If the Millennials' cancer experience follows the estimated trajectory of their proxy parents, cancer incidence in the U.S. could remain unacceptably high for decades to come," the authors write. Abstract/Full Text Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.

临床结果ASCO会议